Fulltext

World Health Organization Generic Protocol to Assess Drug-Resistant HIV Among Children <18 Months of Age and Newly Diagnosed With HIV in Resource-Limited Countries

Bertagnolio, Silvia ; Penazzato, Martina ; Jordan, Michael R. ; Persaud, Deborah ; Mofenson, Lynne M. ; Bennett, Diane E.

In: Clinical Infectious Diseases, 2012, vol. 54, p. S254-S260

Zum persönliche Liste hinzufügen
    Titel
    • World Health Organization Generic Protocol to Assess Drug-Resistant HIV Among Children <18 Months of Age and Newly Diagnosed With HIV in Resource-Limited Countries
    Autor
    • Bertagnolio, Silvia. HIV Department, World Health Organization, Geneva, Switzerland
    • Penazzato, Martina. Department of Pediatrics, University of Padova, Italy
    • Jordan, Michael R.. HIV Department, World Health Organization, Geneva, Switzerland
    • Persaud, Deborah. Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore
    • Mofenson, Lynne M.. Pediatric, Adolescent and Maternal AIDS Branch, National Institutes of Health, Rockville, Maryland
    • Bennett, Diane E.. Global AIDS Program, US Centers for Disease Control and Prevention, Atlanta, Georgia
    Dokumententyp
    • Postprint
    Sprache
    • Englisch
    Veröffentlicht in
    • Clinical Infectious Diseases, 2012, vol. 54, p. S254-S260. Oxford University Press
    Andere elektronische Ausgabe
    Klassifikation
    • Gesundheit
    OAI-PMH-ID
    • oai:doc.rero.ch:295482
    Summary
    Increased use of nonnucleoside reverse transcriptase inhibitors (NNRTIs) in pregnant and breastfeeding women will result in fewer children infected with human immunodeficiency virus (HIV). However, among children infected despite prevention of mother-to-child transmission (PMTCT), a substantial proportion will acquire NNRTI-resistant HIV, potentially compromising response to NNRTI-based antiretroviral therapy (ART). In countries scaling up PMTCT and pediatric ART programs, it is crucial to assess the proportion of young children with drug-resistant HIV to improve health outcomes and support national and global decision making on optimal selection of pediatric first-line ART. This article summarizes a new World Health Organization surveillance protocol to assess resistance using remnant dried blood spot specimens from a representative sample of children aged <18 months being tested for early infant diagnosis